CHRONIC DEMYELINATING NEUROPATHY · AUTOIMMUNE POLYNEUROPATHY
A physician-led, laboratory-verified treatment programme targeting the autoimmune mechanisms behind peripheral nerve demyelination — designed to reduce dependency on immunoglobulin therapy, restore nerve conduction and improve functional independence in CIDP patients.
Request Medical ConsultationAbout the Condition
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an acquired autoimmune disorder of the peripheral nervous system. The immune system attacks the myelin sheath — the insulating layer surrounding peripheral nerves — disrupting signal conduction between the brain, spinal cord and limbs.
Patients typically experience progressive or relapsing weakness in the legs and arms, numbness, tingling, impaired balance and reduced reflexes. Symptoms develop over at least eight weeks, distinguishing CIDP from its acute counterpart, Guillain-Barré syndrome. Without treatment, the condition leads to significant disability — loss of walking ability, chronic pain and dependence on assistance for daily activities.
CIDP affects approximately 1–9 per 100,000 people. Standard treatment relies on intravenous immunoglobulin (IVIG), plasmapheresis and corticosteroids — therapies that suppress the immune response but do not correct the underlying autoimmune dysregulation. A substantial proportion of patients remain dependent on long-term immunomodulatory therapy with incomplete symptom control.
Typical CIDP
Symmetric proximal and distal weakness affecting both upper and lower limbs. Sensory involvement is common. Reflexes are diffusely reduced or absent. This is the most frequently diagnosed form, representing approximately 50–60% of all CIDP cases.
Multifocal CIDP (Lewis-Sumner Syndrome)
Asymmetric motor and sensory involvement, often starting in the upper limbs. Nerve conduction studies show multifocal conduction block. Can be difficult to distinguish from multifocal motor neuropathy. Accounts for approximately 10–15% of CIDP presentations.
Distal CIDP (DADS)
Distal Acquired Demyelinating Symmetric neuropathy. Predominantly affects the hands and feet with sensory symptoms and distal weakness. Often associated with IgM paraproteinaemia. May respond less predictably to standard IVIG therapy.
Sensory-Predominant CIDP
Sensory ataxia, numbness and impaired proprioception dominate the clinical picture, with relatively preserved motor strength. Electrophysiology confirms demyelinating features despite the predominantly sensory presentation. Often underdiagnosed due to minimal motor findings.
Our program is individually adapted for all subtypes and all stages of progression.
Important: Each patient is accepted into the programme only after a comprehensive individual medical assessment, which evaluates diagnosis confirmation, disease activity, current treatment regimen, nerve conduction data and overall clinical profile.
We do not offer a cure for CIDP. Our programme targets the autoimmune mechanisms driving peripheral nerve damage — with the clinical objective of reducing relapse frequency, supporting remyelination, decreasing dependency on immunoglobulin therapy and improving functional independence.
Clinical Outcomes
The following data are derived from structured observational analysis of CIDP patients treated at BioCells Medical between 2016 and 2025. All figures represent aggregated clinical registry outcomes with longitudinal follow-up. These are observational results — not randomised controlled trial data — and do not constitute a guarantee of therapeutic effect.
44
CIDP patients treated
76%
demonstrated measurable functional improvement within 2–5 months
68%
achieved clinically meaningful reduction in INCAT Disability Score
72%
showed improvement in MRC Sum Score (composite limb strength)
61%
reduced IVIG frequency or dosage within 8 months of treatment
70%
maintained functional gains at follow-up beyond 12 months
Improved grip strength and fine motor dexterity
71%
Increased unassisted walking distance and gait stability
64%
Reduced numbness and tingling in hands and feet
58%
Improved proprioception and balance during standing and movement
55%
Decreased reliance on mobility aids (cane, walker, wheelchair)
48%
2–6 weeks
Initial functional response
2–5 months
Clinically meaningful change
1–2 years under continued monitoring
Functional stabilisation phase
Important: Outcomes depend on CIDP subtype, disease duration, baseline INCAT score, current immunomodulatory regimen and individual biological response. Individual results may vary significantly.
Find out if our program can help in your specific case. The initial medical consultation is free and carries no obligation.
Request ConsultationPatient Stories
“I went from IVIG every three weeks to every six. My neurologist agreed to extend the interval after the nerve conduction results came back improved. Half the hospital visits, half the time hooked up to an infusion. That alone changed my life.”
Patient
CIDP (typical) · Italy
Every case is assessed individually by our physician team. Request a consultation to discuss your specific situation with our physician team.
Request ConsultationThe BioCells Program
Our CIDP programme combines five biological components into a single personalised protocol. Each protocol is constructed following a detailed medical evaluation — factoring in disease subtype, nerve conduction findings, current treatment dependency and clinical priorities. No two protocols are identical.
No surgery required
Treatment is delivered by intravenous infusion or targeted local injection using specialised medical systems — not surgical instruments.
No general anaesthesia
The entire treatment protocol is performed without general anaesthesia, eliminating associated recovery time and risk.
No risk of immune rejection — autologous option
Where clinically appropriate, we use the patient's own cells. Zero risk of graft-versus-host disease with autologous protocols.
Targets the autoimmune mechanism, not just symptoms
Standard CIDP therapies suppress the immune system broadly. Our protocol targets the specific immune dysregulation driving demyelination — addressing the cause rather than managing the consequence.
Complements existing CIDP treatment
Our programme is compatible with IVIG, plasmapheresis and corticosteroid regimens. Patients do not need to discontinue existing treatment. The clinical goal is to reduce dependency on these therapies over time — not replace them abruptly.
Treatment at your location worldwide
Our medical team is available to conduct treatment at our Warsaw clinic or to travel to the patient's location anywhere in the world. For patients with significant mobility limitations, this removes a major barrier to accessing care.
What It Is
MSCs are multipotent regenerative cells with demonstrated immunomodulatory and tissue-repair properties. In autoimmune neuropathies, their primary value lies in resetting the dysfunctional immune response that drives demyelination and in supporting the biological conditions for nerve repair.
How It Is Done
Cells are collected from the patient's own bone marrow (autologous, approximately 50 ml under local anaesthesia) or sourced from a certified donor (allogeneic), depending on individual clinical indications. All cells are expanded, quality-controlled and tested in our certified Warsaw laboratory before administration.
Biological Mechanisms
How This Helps in CIDP
In CIDP, the immune system persistently targets the myelin sheath of peripheral nerves. MSCs modulate this autoimmune response at its source — reducing T-cell and B-cell mediated damage to myelin, lowering pro-inflammatory cytokine levels, and supporting the biological conditions that Schwann cells require to begin remyelination of damaged nerve segments.
Your Medical Board
The exact combination, dosage, sequencing and delivery method of all five components is determined individually by our medical board for each patient. No two treatment protocols are identical. Your programme is constructed based on your specific diagnosis, CIDP subtype, nerve conduction data, current immunomodulatory regimen and clinical priorities.
Your protocol is designed individually. Speak with our medical team to understand what your personalised program would include.
Request ConsultationPatient Journey
Your case is reviewed remotely by our physician team. We assess your diagnosis, current INCAT score, nerve conduction data, treatment history and clinical goals. This consultation is free and carries no obligation.
A detailed review of all medical documentation including electrophysiology, MRI, laboratory results and current medication regimen. Our medical board evaluates eligibility, confirms safety parameters and designs your personalised therapeutic protocol.
Your cells are collected, isolated, expanded and quality-tested in our certified Warsaw laboratory. Each batch receives a full traceability certificate. This stage typically takes 2–3 weeks.
Cells are delivered by intravenous infusion or targeted local administration — no surgery, no general anaesthesia. Treatment is available at our Warsaw clinic or with our medical team at your location worldwide. Airport transfers, accommodation and visa support are included in the programme. Where clinically appropriate, our medical board may approve a travelling treatment programme — our medical team flies directly to the patient.
Structured rehabilitation sessions with our specialist, adapted to your current motor and sensory function. Focus on gait retraining, grip strength recovery, proprioceptive exercises and neuropathic pain management. Available at our clinic or remotely coordinated with your local medical team.
Your dedicated coordinator monitors functional status, IVIG dependency, nerve conduction changes and overall well-being. A medical-grade wearable bracelet supports continuous health tracking regardless of your location.
The first step is free. Request a medical consultation and our medical consultant will contact you within 24 hours.
Request ConsultationSafety Profile
Cellular therapy is considered safe when delivered under proper medical supervision and according to validated protocols. In our practice, the procedure is well-tolerated by the majority of CIDP patients.
Temporary mild reactions — such as transient local discomfort at the infusion site, slight fatigue or low-grade temperature — may occur in a minority of patients. These are typically short-lived and indicate active immune engagement.
A final medical assessment is performed on-site before every treatment session. If a patient's clinical status has changed — including active relapse or infection — the programme may be temporarily modified or postponed for safety reasons.
All contraindications are evaluated individually. A contraindication in one clinical context does not necessarily preclude treatment in a different context — this is always determined by physician assessment.
Standard Contraindications
Active acute infection or fever
Active malignancy or ongoing chemotherapy / radiotherapy
Severe decompensated cardiac or renal failure
Pregnancy
Post-Treatment
Dedicated rehabilitation specialist
monitors motor function, sensory recovery and gait stability
Personalised rehabilitation programme
adapted to current functional capacity, CIDP subtype and treatment response
Medical-grade wearable monitoring
continuous physiological data collection supporting clinical decision-making
Long-term coordinator support
proactive check-ins, IVIG tapering guidance and response to any changes in status
Continued clinical access
our medical team remains available for ongoing reassessment and protocol adjustment
Our approach is based on the principle that immune modulation and nerve remyelination require sustained biological support. The period following treatment is as medically important as the treatment itself — particularly for patients adjusting their immunoglobulin regimen in coordination with their local neurologist.
Get Started
If you or someone you care for has been diagnosed with CIDP, our medical team is available for a free, no-obligation medical consultation — based on your diagnosis, current treatment regimen and individual clinical profile.
We review every inquiry personally. You will speak with a physician, not an administrator.
Submit your case online or by phone
Our medical consultant contacts you to review your documents
The medical board presents your personalised treatment plan
Request a Consultation
Tell us about your condition. Our medical consultant will contact you within 24 hours to review your documents.
Open Consultation FormMultilingual coordination — English, Italian, French, Russian, Polish
Evidence Base
Our clinical approach is informed by and consistent with published research in the field of regenerative medicine.
